Seminars in Oncology
Volume 34, Supplement 3 , Pages S17-S22, April 2007

Biomarker Studies and Other Difficult Inferential Problems: Statistical Caveats

  • Donald A. Berry

      Affiliations

    • Dr Berry serves on the Biostatistics Advisory Board for Bristol-Myers Squibb. He has served as a consultant to Eli Lilly and Company and Novartis Pharmaceuticals, and has received honoraria from AstraZeneca Pharmaceuticals LP and Pfizer Inc.
    • Corresponding Author InformationAddress correspondence to Donald A. Berry, PhD, The University of Texas, M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030.

The University of Texas, M. D. Anderson Cancer Center, Houston, TX.

The inferential issues associated with biomarker studies are enormously complex. False-positive conclusions are rampant in the literature. It is wonderful to have many potential biomarkers in trying to explain the heterogeneity of cancer and outcomes of its treatment. But a large number of biomarkers give rise to statistical headaches. False-positives proliferate. A useful approach is to reduce many biomarkers into a single dimension, and to then attempt to confirm the prognostic or predictive value of the single-dimensional quantity. This is not a panacea for all statistical and scientific ailments, but it minimizes some of the problems. A related concern is subset analysis. I give a statistical argument that estrogen-receptor status is predictive of the benefits of chemotherapy in node-positive breast cancer.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0093-7754(07)00068-1

doi:10.1053/j.seminoncol.2007.03.014

Seminars in Oncology
Volume 34, Supplement 3 , Pages S17-S22, April 2007